Ro 31-8220 MesylatePan-PKC inhibitor CAS# 138489-18-6 |
- AVL-292
Catalog No.:BCC1385
CAS No.:1202757-89-8
- QL47
Catalog No.:BCC3920
CAS No.:1469988-75-7
- PCI 29732
Catalog No.:BCC4100
CAS No.:330786-25-9
- CGI-1746
Catalog No.:BCC1473
CAS No.:910232-84-7
- PCI-32765 (Ibrutinib)
Catalog No.:BCC1266
CAS No.:936563-96-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 138489-18-6 | SDF | Download SDF |
PubChem ID | 11628205 | Appearance | Powder |
Formula | C26H27N5O5S2 | M.Wt | 553.65 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Bisindolylmaleimide IX | ||
Solubility | DMSO : ≥ 50 mg/mL (90.31 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | methanesulfonic acid;3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate | ||
SMILES | CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CCCSC(=N)N.CS(=O)(=O)O | ||
Standard InChIKey | SAWVGDJBSPLRRB-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C25H23N5O2S.CH4O3S/c1-29-13-17(15-7-2-4-9-19(15)29)21-22(24(32)28-23(21)31)18-14-30(11-6-12-33-25(26)27)20-10-5-3-8-16(18)20;1-5(2,3)4/h2-5,7-10,13-14H,6,11-12H2,1H3,(H3,26,27)(H,28,31,32);1H3,(H,2,3,4) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Protein kinase C inhibitor, with activity at other protein kinases (IC50 values are 33, 3, 8, 15 and 38 nM for PKCα, MAPKAP-K1b, MSK1, GSK3β and S6K1 respectively). Activates JNK and glycogen synthase, and inhibits MAPK and ERK2, in rat adipocytes and L6 myotubes. Also inhibits voltage-dependent Na+ channels in the micromolar range. |
Ro 31-8220 Mesylate Dilution Calculator
Ro 31-8220 Mesylate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.8062 mL | 9.031 mL | 18.062 mL | 36.1239 mL | 45.1549 mL |
5 mM | 0.3612 mL | 1.8062 mL | 3.6124 mL | 7.2248 mL | 9.031 mL |
10 mM | 0.1806 mL | 0.9031 mL | 1.8062 mL | 3.6124 mL | 4.5155 mL |
50 mM | 0.0361 mL | 0.1806 mL | 0.3612 mL | 0.7225 mL | 0.9031 mL |
100 mM | 0.0181 mL | 0.0903 mL | 0.1806 mL | 0.3612 mL | 0.4515 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ro 31-8220 Mesylate is a selective inhibitor of protein kinase C (PKC) with IC50 values of 5, 24, 14, 27, and 24 nM for PKC α, PKC βI, PKC βII, PKC γ and PKC ε, respectively [1].
PKC is a monomeric Ca2+- and phospholipid-dependent Ser/Thr protein kinases and plays an important role in growth factor-activated signaling and malignant transformation.
Ro 31-8220 Mesylate is a selective inhibitor of PKC. Also, Ro 31-8220 increased growth factor-stimulated expression of c-Jun but inhibited MKP-1 and c-Fos expression. Ro-31-8220 strongly stimulated the stress-activated protein kinase JNK1 in a PKC-independent way [2]. In peripheral blood mononuclear cells, Ro 31-8220 inhibited the production of mitogen-induced interleukin (IL)-2 and IL-2-dependent T lymphoblast proliferation with IC50 values of 80 and 350 nM, respectively. Also, Ro 31-8220 (400 nM) inhibited IL-2Rα (CD25) expression by 27%, which suggested that Ro 31-8220 inhibited early and late T cell activation [3].
In rat adipocytes and L6 myotubes, RO 31-8220 activated c-Jun N-terminal kinase (JNK) and glycogen synthase (GS) and stimulated glucose incorporation into glycogen. While, RO 31-8220 inhibited the activity of extracellular response kinases 1 and 2 (ERK1/2) in a PKC-independent way [4].
References:
[1]. Wilkinson SE, Parker PJ, Nixon JS. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J, 1993, 294 ( Pt 2): 335-337.
[2]. Beltman J, McCormick F, Cook SJ. The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase. J Biol Chem, 1996, 271(43): 27018-27024.
[3]. Geiselhart L, Conti DJ, Freed BM. RO 31-8220, a novel protein kinase C inhibitor, inhibits early and late T cell activation events. Transplantation, 1996, 61(11): 1637-1642.
[4]. Standaert ML, Bandyopadhyay G, Antwi EK, et al. RO 31-8220 activates c-Jun N-terminal kinase and glycogen synthase in rat adipocytes and L6 myotubes. Comparison to actions of insulin.
- FK 888
Catalog No.:BCC5907
CAS No.:138449-07-7
- A 1070722
Catalog No.:BCC7933
CAS No.:1384424-80-9
- Irbesartan
Catalog No.:BCC2560
CAS No.:138402-11-6
- Tinospinoside C
Catalog No.:BCN6925
CAS No.:1383977-51-2
- Afzelechin-(4alpha->8)-epiafzelechin
Catalog No.:BCN7709
CAS No.:1383627-30-2
- Boc-Arg(Tos)-OH
Catalog No.:BCC3067
CAS No.:13836-37-8
- Alvimopan monohydrate
Catalog No.:BCC1349
CAS No.:1383577-62-5
- BD 1047 dihydrobromide
Catalog No.:BCC6863
CAS No.:138356-21-5
- BD 1008 dihydrobromide
Catalog No.:BCC6674
CAS No.:138356-09-9
- CYM 9484
Catalog No.:BCC6238
CAS No.:1383478-94-1
- Hedycoronen A
Catalog No.:BCN7653
CAS No.:1383441-73-3
- Stearyl glycyrrhetinate
Catalog No.:BCN8486
CAS No.:13832-70-7
- S-(+)-Marmesin
Catalog No.:BCN8288
CAS No.:13849-08-6
- 3-Oxopomolic acid
Catalog No.:BCN3485
CAS No.:13849-90-6
- Pomolic acid
Catalog No.:BCN6197
CAS No.:13849-91-7
- Tormentic acid
Catalog No.:BCN6198
CAS No.:13850-16-3
- 9-Hydroxycanthin-6-one
Catalog No.:BCN3105
CAS No.:138544-91-9
- N3PT
Catalog No.:BCC1782
CAS No.:13860-66-7
- NKH 477
Catalog No.:BCC7126
CAS No.:138605-00-2
- (R)-3-Carboxy-4-hydroxyphenylglycine
Catalog No.:BCC6606
CAS No.:13861-03-5
- Securitinine
Catalog No.:BCN6986
CAS No.:13861-71-7
- LP 20 hydrochloride
Catalog No.:BCC6266
CAS No.:1386928-34-2
- Eugenol rutinoside
Catalog No.:BCN6201
CAS No.:138772-01-7
- Fmoc-D-1-Nal-OH
Catalog No.:BCC3284
CAS No.:138774-49-3
Specificity and mechanism of action of some commonly used protein kinase inhibitors.[Pubmed:10998351]
Biochem J. 2000 Oct 1;351(Pt 1):95-105.
The specificities of 28 commercially available compounds reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examined against a large panel of protein kinases. The compounds KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based experiments are likely to be erroneous. Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency. LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase. The compounds with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190. U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly. Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one additional protein kinase. Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure. We propose guidelines for the use of protein kinase inhibitors in cell-based assays.
Inhibition of voltage-dependent sodium channels by Ro 31-8220, a 'specific' protein kinase C inhibitor.[Pubmed:10812087]
FEBS Lett. 2000 May 12;473(2):265-8.
We find that several protein kinase C (PKC) inhibitors, previously considered to be specific, directly inhibit voltage-dependent Na(+) channels at their useful concentrations. Bisindolylmaleimide I (GF 1092037), IX (Ro 31-8220) and V (an inactive analogue), but not H7 (a non-selective isoquinolinesulfonamide protein kinase inhibitor), inhibited Na(+) channels assessed by several independent criteria: Na(+) channel-dependent glutamate release and [(3)H]batrachotoxinin-A 20-alpha-benzoate binding in rat cortical synaptosomes, veratridine-stimulated 22Na(+) influx in CHO cells expressing rat CNaIIa Na(+) channels and Na(+) currents measured in isolated rat dorsal root ganglion neurons by whole cell patch-clamp recording. These findings limit the usefulness of the bisindolylmaleimide class PKC inhibitors in excitable cells.
Potent selective inhibitors of protein kinase C.[Pubmed:2532156]
FEBS Lett. 1989 Dec 18;259(1):61-3.
A series of potent, selective inhibitors of protein kinase C has been derived from the structural lead provided by the microbial broth products, staurosporine and K252a. Our inhibitors block PCK in intact cells (platelets and T cells), and prevent the proliferation of mononuclear cells in response to interleukin 2 (IL2).